30-Second Takeaway
- Bayesian reanalysis suggests prehospital TXA likely reduces mortality in bleeding trauma patients despite a neutral STAAMP trial.
- ISS-based AI plus demographics predicts in-hospital trauma mortality accurately and more fairly across age and sex groups.
- Emerging neurotrauma work targets vascular stability, ferroptosis, and age–sex differences to refine TBI care and trial design.
- Early CT and POCUS after in-hospital arrest frequently uncover treatable pathology and clarify arrest cause with low risk.
- ICU tools—from restraint strategies to RRT weaning scores—can guide safer de-escalation and recovery planning for trauma patients.
Week ending March 21, 2026
Trauma resuscitation, neuroprotection, and ICU decision tools: what’s new for the trauma surgeon
Bayesian reanalysis of STAAMP supports a mortality benefit from prehospital TXA
This Bayesian reanalysis revisits prehospital tranexamic acid (TXA) for trauma patients at risk for hemorrhage in STAAMP. Conventional analysis showed numerically lower 30-day mortality with TXA (8.1% vs 9.9%) but a nonsignificant hazard ratio of 0.81. Bayesian models using CRASH-2 or PATCH-Trauma priors yielded posterior risk ratios between 0.80 and 0.91, favoring TXA. The posterior probability that TXA reduced mortality ranged from 84% to 99% across priors and sensitivity analyses. These results indicate a high probability of survival benefit from prehospital TXA despite the neutral frequentist primary analysis.
ISS-plus-demographics AI model predicts trauma mortality accurately and more fairly
This multicenter study developed an AI model combining Injury Severity Score, age, and sex to predict in-hospital trauma mortality. Using 121,418 Korean trauma patients for development, the model achieved an internal AUROC of 0.934. External validation in 7,458 patients from five trauma centers yielded AUROCs between 0.901 and 0.920, outperforming conventional ISS-based methods. The AI approach reduced performance gaps between younger and older patients, and between men and women, compared with ISS alone. Such models could support more equitable triage, benchmarking, and resource allocation across diverse trauma populations.
Dried platelet-derived biologic limits hemorrhage and BBB injury after TBI in mice
This preclinical study tested a freeze-dried platelet-derived biologic (FDPlts) in a murine traumatic brain injury model. FDPlt transfusion reduced intracranial hemorrhage and restored cerebral vascular perfusion after TBI. FDPlts also decreased blood-brain barrier permeability, intravascular leukocytosis, and neuroinflammation, including microglial and astrocytic activation. Transcriptomics showed downregulation of inflammatory and fibrotic gene networks in cortex and hippocampus with FDPlt treatment. FDPlts were enriched in Angiopoietin-1 and acted via Tie2-dependent endothelial stabilization, supporting a vascular repair mechanism. These findings suggest dried platelet-derived products as potential future adjuncts for hemorrhagic TBI and damage-control resuscitation.
References
Numbered in order of appearance. Click any reference to view details.
Additional Reads
Optional additional studies from this edition.